Blackhawk Capital Partners LLC. Grows Stake in Novo Nordisk A/S (NYSE:NVO)

Blackhawk Capital Partners LLC. boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 4.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,411 shares of the company’s stock after acquiring an additional 251 shares during the period. Blackhawk Capital Partners LLC.’s holdings in Novo Nordisk A/S were worth $763,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. International Assets Investment Management LLC boosted its position in shares of Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after acquiring an additional 1,796,635 shares during the last quarter. DSM Capital Partners LLC increased its stake in Novo Nordisk A/S by 257,816.0% during the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after acquiring an additional 1,593,303 shares during the last quarter. Mediolanum International Funds Ltd purchased a new stake in Novo Nordisk A/S during the 3rd quarter valued at $98,765,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Novo Nordisk A/S by 10.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 8,589,222 shares of the company’s stock worth $1,102,857,000 after purchasing an additional 823,036 shares during the period. Finally, Marshall Wace LLP raised its position in Novo Nordisk A/S by 34,472.1% in the 2nd quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock worth $98,696,000 after purchasing an additional 689,441 shares during the period. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Up 2.6 %

Shares of NVO stock opened at $105.30 on Thursday. Novo Nordisk A/S has a 1-year low of $94.73 and a 1-year high of $148.15. The company has a market cap of $472.51 billion, a price-to-earnings ratio of 34.08, a price-to-earnings-growth ratio of 1.32 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The stock’s fifty day moving average price is $116.80 and its 200 day moving average price is $129.11.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Finally, BMO Capital Markets lowered their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.